Non-communicable disease

Global Clinical Trial Management System (CTMS) Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 18, 2022
Health, Data Management, Technology, Clinical Trials, Software, ZINC, Diabetes, Merck & Co., Pfizer, Clinical data management, Death, Chronic lung disease, Non-communicable disease, Conditional sentence, Food, Degenerative disease, World, Moyamoya disease, Clinical, Fatality, FAO, IHD, Clinical trial, CHEMBL, Stroke, COVID-19, Clinical trial management system, Food and Agriculture Organization, Merck, Research, FDA, Efficiency, Awareness, Time, Biotechnology, WHO, CTMS, III, Congressional Budget Office, NCD, CAGR, Prevalence, Cancer, Data management, Medical device, Pharmaceutical industry, Alphabet

The "Global Clinical Trial Management System (CTMS) Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Clinical Trial Management System (CTMS) Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Clinical Trial Management System (CTMS) is a software system used by biotechnology and pharmaceutical industries to handle clinical trials in clinical research.
  • Furthermore, increasing innovative technology developments to reduce the rising cost of clinical trials have resulted in the development of the clinical trial management system.
  • Thus, the increasing number of clinical research studies will boost the use of clinical trial management system solutions, therefore increasing market value.

Outlook on the Veterinary Diagnostics Global Market to 2030 - Featuring Zoetis, Heska and Thermo Fisher Scientific Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 22, 2022
Veterinary, Health, Pandemic, CAGR, Hematology, Biomarker, Population, USD, State, Non-communicable disease, WGS, Hospital Insurance and Diagnostic Services Act, Growth, IVD, Immunoassay, Pathology, Group of Seven, Incidence, PETS, Birth, Element, Nanotechnology, COVID-19, Lists of countries and territories, Income, Animal, Efficiency, Heredity, Livestock, Partnership, Vaccine, Pet, Medical device, Labs

The global veterinary diagnostics market size is expected to reach USD 16.9 billion by 2030.

Key Points: 
  • The global veterinary diagnostics market size is expected to reach USD 16.9 billion by 2030.
  • The market is expected to expand at a CAGR of 11.2% from 2022 to 2030.
  • The growing incidence of zoonotic and foodborne diseases is expected to drive the market over the forecast period.
  • Moreover, increasing companion ownership in developing countries is another factor propelling the market.

South African Non-Communicable Diseases Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022
Health, Other Health, Cerebrovascular disease, Degenerative disease, Diabetes, Research, Rheumatoid arthritis, Prevalence, Death, Cardiovascular disease, Disease, Life expectancy, Blaenavon Industrial Landscape, Fertility, COVID-19, Parkinson's disease, Non-communicable disease, NCD, Mortality, Global health, Alzheimer's disease, Pharmaceutical industry, Hyperlipidemia, Hypertension, Cancer, Cancer, African

The "South African Non-Communicable Diseases (NCD) Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "South African Non-Communicable Diseases (NCD) Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides a dynamic synthesis of medical research, examining global and South African prevalence, current treatment, new medical research and advancements for these major NCDs: Cardiovascular Diseases, Hyperlipidemia, Hypertension, Cerebrovascular Diseases, Diabetes Mellitus, Cancer, Rheumatoid Arthritis, Alzheimer's Disease, Parkinson's Disease.
  • The South African Non-Communicable Diseases Industry Landscape Report 2021 provides a holistic overview of the global and South African market and will help answer the following questions:
    What are the global and South African health indicators?
  • This report covers the following categories:
    The Non-Communicable Diseases report provides insights and advancements into Cardiovascular Diseases, Hyperlipidemia, Hypertension, Cerebrovascular Diseases, Diabetes Mellitus, Cancer, Rheumatoid Arthritis, Alzheimer's Disease, and Parkinson's Disease.

UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents

Retrieved on: 
Wednesday, February 2, 2022
CEO, Private Securities Litigation Reform Act, Government, View, Patient, Overalls, NCD, Mortality, Global Burden of Disease Study, Degenerative disease, LLY, Sickle cell disease, Non-communicable disease, Death, Form, UNICEF, Cardiovascular disease, Asthma, Primary health care, Cancer, Disease, Private sector, U.S. Fund for UNICEF, Child, Risk, Health, Geography, Education, Investment, SDG3, Form 10-K, NYSE, Multimedia, Sustainable Development Goals, U.S. Securities and Exchange Commission, Pharmaceutical industry, Cryptocurrency, Lilly

NEW YORKand INDIANAPOLIS, Feb. 2, 2022 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced anew collaboration tohelp improve health outcomes for 10 million children and adolescents living with chronic, non-communicable diseases (NCDs) through 2025.

Key Points: 
  • NEW YORKand INDIANAPOLIS, Feb. 2, 2022 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced anew collaboration tohelp improve health outcomes for 10 million children and adolescents living with chronic, non-communicable diseases (NCDs) through 2025.
  • Non-communicable diseases undermine a child's right to health, nutrition, education and play," said Karin Hulshof, Deputy Executive Director, UNICEF.
  • "We are grateful to Lilly for this collaboration to help strengthen health care systems children rely on and ensure health care workers are well-equipped and confident in providing care and treatment to children living with chronic conditions."
  • 1Donations from Lilly will go directly to the U.S. Fund for UNICEF, the tax-exempt organization that supports UNICEF's global work.

In Vitro Diagnostics Quality Control Market, by Source, Technology, Manufacturer, End-users and Region - Global Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Science, Health, Research, OEM, Hospital, Data management, CAGR, Non-communicable disease, Molecular diagnostics, Plasma, Product-service system, Decision-making, Laboratory, Immunoassay, Microbiology, USD, Industry, Solution, IVD, Growth, Hemostasis, Research, Immunochemistry, Medical device, Vaccine, Healthcare

The global IVD quality control market is projected to reach USD 1.4 billion by 2026 from USD 1.1 billion in 2021, at a CAGR of 5.3% during the forecast period.

Key Points: 
  • The global IVD quality control market is projected to reach USD 1.4 billion by 2026 from USD 1.1 billion in 2021, at a CAGR of 5.3% during the forecast period.
  • Based on product & service, the IVD quality control market is segmented into quality control products, data management solutions, and quality assurance services.
  • The quality control products segment accounted for the largest share of the IVD quality control market in 2020.
  • The APAC region has the highest CAGR of the global IVD quality control market.

Global Angioscope Device Market (2021 to 2026) - by Type, Procedure, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Medical Devices, Health, Cardiovascular diseases, Global health, Non-communicable disease, Cardiovascular disease

One of the major factors anticipated to drive the growth of the global angioscope device market during the forecast period is the research and developments being conducted in angiography and the consequent innovations, which are providing advancements in angioscopy.

Key Points: 
  • One of the major factors anticipated to drive the growth of the global angioscope device market during the forecast period is the research and developments being conducted in angiography and the consequent innovations, which are providing advancements in angioscopy.
  • The growing cases of cardiovascular diseases around the world have led to the increased use of angioscopy, which is anticipated to surge the growth of the global angioscope device market during the forecast period.
  • The increased threat due to CVDs has led to increased demand for angioscope, which is anticipated to propel the growth of the global angioscope device market during the assessment period.
  • The Asia Pacific region is anticipated to witness substantial growth due to rising investment in healthcare and the growing number of CVD cases.

Relentless Adds AI-Powered Platform Dedicated to CNS Chronic Care Management to the Portfolio

Retrieved on: 
Thursday, August 19, 2021
Well, United Nations Sustainable Development Group, Massachusetts General Hospital, Non-communicable disease, Ageing, CNS, NYU, Seed, UCSF, Adoption, Speech, Human, Longevity, Life, Movement, Diagnosis, Intention, Conditional sentence, GLOBE, Artificial intelligence, Biomarker, Diabetes, Purdue University, Data, Machine learning, Director, Health, Schizophrenia, Autism, CA, Software as a service, Time, AI, MGH, Board, Mortality, SDG, Patient, Partnership, Depression, CEO, Mass, Hospital, Publication, Cardiovascular disease, Relentless, Technology, Medical imaging, Pharmaceutical industry, Tutoring

Relentless Managing Partner Brenda Irwin shared that team investment interest piqued following the release of data from an in-clinic pilot with schizophrenia patients.

Key Points: 
  • Relentless Managing Partner Brenda Irwin shared that team investment interest piqued following the release of data from an in-clinic pilot with schizophrenia patients.
  • We are on a relentless hunt for innovative care options across the spectrum of mental health disorders.
  • In addition, they have a growing dataset across a number of other chronic diseases including Parkinsons and Autism Spectrum Disorder.
  • We are keen to work with a team uniquely committed to data-driven outcomes in new approaches to chronic care management.

The Worldwide Pharmaceutical Packaging Industry Is Expected to Reach $151.08 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 12, 2021
Packaging, Pharmaceutical, Health, Manufacturing, Government, Drug development, Research, Non-communicable disease, Population, COVID-19, Ageing, Pharmaceutical industry

The "Global Pharmaceutical Packaging Market 2020-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pharmaceutical Packaging Market 2020-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global pharmaceutical packaging market will reach $151.08 billion by 2027, growing by 6.8% annually over 2020-2027 owing to the increase in healthcare coverage, growing aging population, an increase in non-communicable disease, new drug development and government initiatives to promote innovations in the pharmaceutical industry.
  • This report is based on a comprehensive research of the entire global pharmaceutical packaging market and all its sub-segments through extensively detailed classifications.
  • Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.

Press release - Enhancing EU’s disease prevention and control capacity

Retrieved on: 
Tuesday, June 29, 2021
Articles, Health, Medical terminology, Global health, Non-communicable disease, Disease, European Centre for Disease Prevention and Control, Preventive healthcare, Public health

The Committee on the Environment, Public Health and Food Safety (ENVI) adopted on Tuesday, with 67 votes in favour, 8 against and 1 abstention, its position on reinforcing the mandate of the European Centre for Disease Prevention and Control (ECDC).

Key Points: 
  • The Committee on the Environment, Public Health and Food Safety (ENVI) adopted on Tuesday, with 67 votes in favour, 8 against and 1 abstention, its position on reinforcing the mandate of the European Centre for Disease Prevention and Control (ECDC).
  • Inclusion of major non-communicable diseases

    MEPs propose that, alongside communicable diseases, the ECDCs mandate should also cover major non-communicable diseases, such as cardiovascular and respiratory diseases, cancer, diabetes and mental illness.

  • In addition, the Centre and national authorities should agree on common timelines, case definitions, indicators, standards, protocols and procedures.
  • Finally, I am satisfied that the EU preparedness plan will be developed through the adoption of national plans.

One Year After COVID-19 Global Lockdown, Medical Panel Discusses Pandemic Impact on Patients with Underlying Conditions and the Need to Prioritize Chronic Diseases in the Future

Retrieved on: 
Tuesday, April 20, 2021
Public health, Health, Articles, COVID-19, Occupational safety and health, Zoonoses, LinkedIn, Non-communicable disease

"Investing in healthcare infrastructure expands access to care and services to those who need it the most, such as those most at-risk for severe complications of COVID-19.

Key Points: 
  • "Investing in healthcare infrastructure expands access to care and services to those who need it the most, such as those most at-risk for severe complications of COVID-19.
  • "People living with NCDs are at higher risk of severe COVID-19-related illness and death, based on 4 key NCDs and 5 NCD risk factors.
  • With a global workforce of approximately 45,000,Viatrisis headquarter in theU.S., with global centers inPittsburgh,Shanghaiin China andHyderabad in India.
  • Learn moreat viatris.com and investor.viatris.com , and connect with us on Twitterat @ViatrisInc , LinkedIn and YouTube .\n'